Nautilus Biotechnology - About the company
Nautilus Biotechnology is a public company based in Seattle (United States), founded in 2016 by Sujal Patel and Parag Mallick. It operates as a Developer of proteomics platform for drug development. Nautilus Biotechnology has raised $453M in funding from Vulcan. The company has 174 active competitors, including 30 funded and 27 that have exited. Its top competitors include companies like Somalogic, Biognosys and Arzeda.
Company Details
Nautilus Biotechnology is developing a proteomics platform for analyzing and quantifying the human proteome. The company is developing a platform with sensitivity for protein quantification and analysis for the study of human proteins using its patent-protected technology. It is used for drug development and precision medicine.
- Website
- nautilus.bio
- Email ID
- *****@nautilus.bio
- Phone Number
- +1 **********
- Registered Address
- 2701 Eastlake Avenue East Seattle, Washington
Key Metrics
Founded Year
2016
Location
Seattle, United States
Stage
Public
Total Funding
$453M in 5 rounds
Latest Funding Round
Ranked
1st among 174 active competitors
Employee Count
149 as on Jun 30, 2026
Exit Details
Public
Legal entities associated with Nautilus Biotechnology
Nautilus Biotechnology is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
NAUTILUS BIOTECHNOLOGY, INC CIN: 98-1541723 , United States, Active | Dec 31, 2015 | - | 134 (As on Dec 31, 2022) | - |
Nautilus Biotechnology, Inc. CIN: 1808805 , United States, Active | Jun 08, 2021 | - | - | - |
Nautilus Biotechnology's IPO details
Nautilus Biotechnology got listed on Jun 10, 2021.
Click here to take a look at Nautilus Biotechnology's IPO in detail
Sign up to download Nautilus Biotechnology's company profile
Nautilus Biotechnology's funding and investors
Nautilus Biotechnology has raised a total funding of $453M over 5 rounds. Its first funding round was on May 30, 2018. Its latest funding round was a Post IPO round on Aug 05, 2021 for $*****. 1 investor participated in its latest round. Nautilus Biotechnology has 10 institutional investors.
Here is the list of recent funding rounds of Nautilus Biotechnology:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 05, 2021 | 3592582 | Post IPO | 2228729 | 5339694 | 2389164 | 8138919 |
Jun 22, 2021 | 4660797 | Post IPO | 7232812 | 3318914 | 6599023 | 8272507 |
Feb 08, 2021 | 1890480 | Series C | 6460427 | 2309422 | 9791804 | 7468569 |
View details of Nautilus Biotechnology's funding rounds and investors
Nautilus Biotechnology's founders and board of directors
Founder? Claim ProfileThe founders of Nautilus Biotechnology are Sujal Patel and Parag Mallick. Sujal Patel is the CEO of Nautilus Biotechnology.
Here are the details of Nautilus Biotechnology's key team members:
- Sujal Patel: Co-Founder & CEO of Nautilus Biotechnology and founder of 1 other company. They are also an angel investor in 1 startup and serve on the boards of 2 companies.Contact Info: 1 email address
- Parag Mallick: Co-Founder of Nautilus Biotechnology. Contact Info: 1 email address
View details of Nautilus Biotechnology's Founder profiles and Board Members
Nautilus Biotechnology's employee count trend
Nautilus Biotechnology has 149 employees as of Jun 26. Here is Nautilus Biotechnology's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Nautilus Biotechnology's Competitors and alternates
Top competitors of Nautilus Biotechnology include Somalogic, Biognosys and Arzeda. Here is the list of Top 10 competitors of Nautilus Biotechnology, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Nautilus Biotechnology 2016, Seattle (United States), Public | Developer of proteomics platform for drug development | $453M | 65/100 | |
2nd | Somalogic 1999, Boulder (United States), Acquired | Developer of protein-based assays for life science research | $664M | 64/100 | |
3rd | Biognosys 2008, Schlieren (Switzerland), Acquired | Provider of proteomics service | $9.13M | 63/100 | |
4th | Arzeda 2008, Seattle (United States), Series B | Developer of enzyme design technology to bridge the gap by creating synthetic enzymes | $95.2M | 59/100 | |
5th | A-Alpha Bio 2017, Seattle (United States), Series A | Developer of cell-based tool for the measurements of protein interactions | $45.2M | 57/100 | |
6th | Mursla 2017, London (United Kingdom), Seed | Provider of diagnostic device for cancer detection | $547K | 55/100 | |
7th | ProteinSimple 2004, San Jose (United States), Acquired | Provider tools to help researchers with protein analysis | $94.3M | 54/100 | |
8th | Amunix 2006, Mountain View (United States), Acquired | Developer of peptide-based therapeutics | $201M | 49/100 | |
9th | Dynamic Biosensors 2011, Planegg (Germany), Acquired | Provides solutions for label-free molecular interaction and biophysical analysis | $5.83M | 49/100 | |
10th | Akonni 2003, Frederick (United States), Series C | Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification | $39.7M | 49/100 |
Looking for more details on Nautilus Biotechnology's competitors? Click here to see the top ones
Nautilus Biotechnology's Investments and acquisitions
Nautilus Biotechnology has made no investments or acquisitions yet.
Reports related to Nautilus Biotechnology
Here is the latest report on Nautilus Biotechnology's sector:
News related to Nautilus Biotechnology
Media has covered Nautilus Biotechnology for a total of 7 events in the last 1 year, 2 of them have been about company updates.
•
Nautilus Biotechnology Reports Second Quarter 2026 Financial ResultsGlobeNewswire•Jul 28, 2026•Nautilus Biotechnology
•
Nautilus Biotechnology Reports First Quarter 2026 Financial ResultsGlobeNewswire•Apr 28, 2026•Nautilus Biotechnology
•
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsGlobeNewswire•Feb 26, 2026•Nautilus Biotechnology
•
•
Nautilus Biotechnology Reports Third Quarter 2025 Financial ResultsGlobeNewswire•Oct 28, 2025•Nautilus Biotechnology
•
Nautilus Biotechnology (NASDAQ:NAUT) CEO Acquires 116,500 Shares of StockMarketBeat•Sep 12, 2025•Nautilus Biotechnology
•
Nautilus Biotechnology Reports Second Quarter 2025 Financial ResultsGlobeNewswire•Jul 31, 2025•Nautilus Biotechnology
•
Nautilus Biotechnology Reports First Quarter 2025 Financial ResultsGlobeNewswire•Apr 29, 2025•Nautilus Biotechnology
•
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsGlobeNewswire•Feb 27, 2025•Nautilus Biotechnology
•
Nautilus Biotechnology Reports Third Quarter 2024 Financial ResultsGlobeNewswire•Oct 29, 2024•Nautilus Biotechnology
Are you a Founder ?
FAQs about Nautilus Biotechnology
Explore our recently published companies
